(Reuters) - "There is a problem in manufacturing," said a spokesman for
the European Medicines Agency, explaining the sudden decision.
Patients taking Viracept, a first-line HIV therapy, are
being urged to contact their doctor and will have to change to
another appropriate medicine.
Read more at Reuters.com Government Filings News
the European Medicines Agency, explaining the sudden decision.
Patients taking Viracept, a first-line HIV therapy, are
being urged to contact their doctor and will have to change to
another appropriate medicine.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment